Hartmut Grasemann

List of Publications by Year
in descending order

119	5,614	76326	85541
papers	citations	40 h-index	71 g-index

123	123	123	7132
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	SK3 channel and mitochondrial ROS mediate NADPH oxidase-independent NETosis induced by calcium influx. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2817-2822.	7.1	558
2	Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. New England Journal of Medicine, 2016, 374, 1842-1852.	27.0	456
3	Exhaled Nitric Oxide in Pulmonary Diseases. Chest, 2010, 138, 682-692.	0.8	347
4	Contribution of Nitric Oxide Synthases 1, 2, and 3 to Airway Hyperresponsiveness and Inflammation in a Murine Model of Asthma. Journal of Experimental Medicine, 1999, 189, 1621-1630.	8.5	195
5	Akt is essential to induce NADPH-dependent NETosis and to switch the neutrophil death to apoptosis. Blood, 2014, 123, 597-600.	1.4	133
6	JNK Activation Turns on LPS- and Gram-Negative Bacteria-Induced NADPH Oxidase-Dependent Suicidal NETosis. Scientific Reports, 2017, 7, 3409.	3.3	130
7	Functionally important role for arginase 1 in the airway hyperresponsiveness of asthma. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L911-L920.	2.9	121
8	Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth. European Respiratory Journal, 2015, 46, 1033-1045.	6.7	120
9	Innate Immune Collectin Surfactant Protein D Simultaneously Binds Both Neutrophil Extracellular Traps and Carbohydrate Ligands and Promotes Bacterial Trapping. Journal of Immunology, 2011, 187, 1856-1865.	0.8	117
10	Inhalation of Moli1901 in Patients With Cystic Fibrosis. Chest, 2007, 131, 1461-1466.	0.8	116
11	Exhaled Nitric Oxide in Patients with Asthma. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 2043-2047.	5.6	115
12	Airway Nitric Oxide Levels in Cystic Fibrosis Patients Are Related to a Polymorphism in the Neuronal Nitric Oxide Synthase Gene. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 2172-2176.	5.6	109
13	Increased Arginase Activity in Cystic Fibrosis Airways. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1523-1528.	5.6	109
14	Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. Journal of Pediatrics, 1999, 135, 770-772.	1.8	97
15	Asymmetric Dimethylarginine Is Increased in Asthma. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 779-785.	5.6	93
16	Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 433-439.	0.7	84
17	Early lung disease in cystic fibrosis. Lancet Respiratory Medicine,the, 2013, 1, 148-157.	10.7	80
18	Longitudinal Decline in Lung Volume in a Population of Children with Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1055-1059.	5.6	78

#	Article	IF	Citations
19	Inhaledl-Arginine Improves Exhaled Nitric Oxide and Pulmonary Function in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 208-212.	5.6	76
20	Diagnostic value of serum antibodies in earlyPseudomonas aeruginosa infection in cystic fibrosis patients. Pediatric Pulmonology, 2007, 42, 249-255.	2.0	69
21	Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. European Respiratory Journal, 2016, 47, 829-836.	6.7	66
22	Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation. Genes, 2019, 10, 183.	2.4	65
23	Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 755-762.	0.7	62
24	Association of a Missense Mutation in theNOS3Gene with Exhaled Nitric Oxide Levels. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 228-231.	5.6	61
25	Diagnostic Value of Nasal Nitric Oxide Measured with Non-Velum Closure Techniques for Children with Primary Ciliary Dyskinesia. Journal of Pediatrics, 2011, 159, 420-424.	1.8	60
26	Endothelial Nitric Oxide Synthase Variants in Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 390-394.	5.6	59
27	Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis. Respiratory Research, 2006, 7, 87.	3.6	54
28	Increased Ornithine-Derived Polyamines Cause Airway Hyperresponsiveness in a Mouse Model of Asthma. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 694-702.	2.9	52
29	Transducing Airway Basal Cells with a Helper-Dependent Adenoviral Vector for Lung Gene Therapy. Human Gene Therapy, 2018, 29, 643-652.	2.7	52
30	Asymmetric Dimethylarginine Contributes to Airway Nitric Oxide Deficiency in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1363-1368.	5.6	51
31	A randomized controlled trial of inhaled l-Arginine in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 468-474.	0.7	48
32	Regulating NETosis: Increasing pH Promotes NADPH Oxidase-Dependent NETosis. Frontiers in Medicine, 2018, 5, 19.	2.6	48
33	L-Citrulline increases nitric oxide and improves control in obese asthmatics. JCI Insight, 2019, 4, .	5.0	48
34	Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis. Current Pharmaceutical Design, 2012, 18, 726-736.	1.9	47
35	The Transcription Factor Early Growth-response Factor 1 Modulates Tumor Necrosis Factor- Î± , Immunoglobulin E, and Airway Responsiveness in Mice. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 778-785.	5.6	46
36	Effects of Sex and of Gene Variants in Constitutive Nitric Oxide Synthases on Exhaled Nitric Oxide. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1113-1116.	5.6	45

#	Article	IF	Citations
37	Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 262-266.	0.7	45
38	Cystic fibrosis lung disease: The role of nitric oxide. Pediatric Pulmonology, 1999, 28, 442-448.	2.0	44
39	Sputum Induction in Routine Clinical Care of Children with Cystic Fibrosis. Journal of Pediatrics, 2010, 157, 1006-1011.e1.	1.8	43
40	L-Ornithine Derived Polyamines in Cystic Fibrosis Airways. PLoS ONE, 2012, 7, e46618.	2.5	43
41	Cystic Fibrosis: Detecting Changes in Airway Inflammation with FDG PET/CT. Radiology, 2012, 264, 868-875.	7.3	42
42	Arginase inhibition prevents bleomycin-induced pulmonary hypertension, vascular remodeling, and collagen deposition in neonatal rat lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L503-L510.	2.9	42
43	Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms. Scientific Reports, 2018, 8, 14728.	3.3	42
44	Interacting genetic loci cause airway hyperresponsiveness. Physiological Genomics, 2005, 21, 105-111.	2.3	41
45	Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 1224-1232.	2.0	41
46	The role of the endothelin-1 pathway as a biomarker for donor lung assessment in clinical ex vivo lung perfusion. Journal of Heart and Lung Transplantation, 2015, 34, 849-857.	0.6	41
47	Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways. International Journal of Molecular Sciences, 2021, 22, 2155.	4.1	38
48	CFTR Modulator Therapy for Cystic Fibrosis. New England Journal of Medicine, 2017, 377, 2085-2088.	27.0	37
49	Augmentation of arginase 1 expression by exposure to air pollution exacerbates the airways hyperresponsiveness in murine models of asthma. Respiratory Research, 2011, 12, 19.	3.6	36
50	Lung transplantation for cystic fibrosis. Journal of Heart and Lung Transplantation, 2020, 39, 553-560.	0.6	36
51	Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD). International Journal of Molecular Sciences, 2014, 15, 6062-6071.	4.1	34
52	Lung Clearance Index to Track Acute Respiratory Events in School-Age Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 977-986.	5.6	34
53	Interleukin-8 receptor modulates IgE production and B-cell expansion and trafficking in allergen-induced pulmonary inflammation. Journal of Clinical Investigation, 1999, 103, 507-515.	8.2	34
54	Necrotizing Pneumonia Complicated by Early and Late Pneumatoceles. Canadian Respiratory Journal, 2008, 15, 129-132.	1.6	33

#	Article	IF	Citations
55	Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 727-732.	0.7	32
56	Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 526-528.	5.6	32
57	A randomized clinical trial of age and genotypeâ€guided tacrolimus dosing after pediatric solid organ transplantation. Pediatric Transplantation, 2018, 22, e13285.	1.0	31
58	Simple Tandem Repeat Polymorphisms in the Neuronal Nitric Oxide Synthase Gene in Different Ethnic Populations. Human Heredity, 1999, 49, 139-141.	0.8	30
59	Airway nitric oxide in infants with acute wheezy bronchitis. Pediatric Allergy and Immunology, 2000, 11, 230-235.	2.6	30
60	Dornase alpha and exhaled NO in cystic fibrosis. Pediatric Pulmonology, 2004, 38, 379-385.	2.0	30
61	Emerging therapies for cystic fibrosis lung disease. Expert Opinion on Emerging Drugs, 2010, 15, 653-659.	2.4	29
62	Developmental changes in arginase expression and activity in the lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L498-L504.	2.9	27
63	Oxidative stress and obesity-related asthma. Paediatric Respiratory Reviews, 2021, 37, 18-21.	1.8	27
64	Potential of the Electronic Nose for the Detection of Respiratory Diseases with and without Infection. International Journal of Molecular Sciences, 2020, 21, 9416.	4.1	25
65	Arginine Therapy for Lung Diseases. Frontiers in Pharmacology, 2021, 12, 627503.	3.5	25
66	Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374, 65-77.	3.0	24
67	Energy Expenditure and Nutritional Status in Pediatric Patients before and after Lung Transplantation. Journal of Pediatrics, 2013, 163, 1500-1502.	1.8	24
68	Pulmonary Venoocclusive Disease in Childhood. Chest, 2014, 146, 167-174.	0.8	24
69	Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis. European Respiratory Journal, 2021, 58, 2003380.	6.7	24
70	Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. Journal of Cystic Fibrosis, 2012, 11, 63-67.	0.7	22
71	Lower Airway Nitric Oxide is Increased in Children with Sickle Cell Disease. Journal of Pediatrics, 2012, 160, 93-97.	1.8	22
72	Aquagenic Wrinkling of the Palms in a Patient with Cystic Fibrosis. New England Journal of Medicine, 2013, 369, 2362-2363.	27.0	22

#	Article	IF	Citations
73	New Therapies in Cystic Fibrosis. Current Pharmaceutical Design, 2012, 18, 614-627.	1.9	21
74	Effect of Hydroxyurea Therapy on Pulmonary Function in Children with Sickle Cell Anemia. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 689-691.	5.6	21
75	Arginine Metabolism in Asthma. Immunology and Allergy Clinics of North America, 2014, 34, 767-775.	1.9	20
76	Genetics and Genomics of Longitudinal Lung Function Patterns in Individuals with Asthma. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1465-1474.	5.6	20
77	Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations. European Respiratory Journal, 2017, 50, 1700244.	6.7	20
78	A Lipid Mediator Hepoxilin A3 Is a Natural Inducer of Neutrophil Extracellular Traps in Human Neutrophils. Mediators of Inflammation, 2015, 2015, 1-7.	3.0	19
79	Effect of Arginase Inhibition on Pulmonary L-Arginine Metabolism in Murine Pseudomonas Pneumonia. PLoS ONE, 2014, 9, e90232.	2.5	19
80	CFTR Mutations in Turkish and North African Cystic Fibrosis Patients in Europe: Implications for Screening. Genetic Testing and Molecular Biomarkers, 2008, 12, 25-35.	1.7	18
81	Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vasoâ€occlusive pain. American Journal of Hematology, 2019, 94, 689-696.	4.1	17
82	Overcoming the Undesirable CRISPR-Cas9 Expression in Gene Correction. Molecular Therapy - Nucleic Acids, 2018, 13, 699-709.	5.1	15
83	Asymmetric Dimethylarginine. Chest, 2013, 144, 367-368.	0.8	13
84	Comparison of a handheld turbine spirometer to conventional spirometry in children with cystic fibrosis. Pediatric Pulmonology, 2020, 55, 1394-1399.	2.0	13
85	Exhaled Nitric Oxide in Children after Accidental Exposure to Chlorine Gas. Inhalation Toxicology, 2007, 19, 895-898.	1.6	12
86	Chronic hypercapnia downregulates arginase expression and activity and increases pulmonary arterial smooth muscle relaxation in the newborn rat. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L777-L784.	2.9	12
87	Asymmetric dimethylarginine and asthma. European Respiratory Journal, 2014, 43, 647-648.	6.7	12
88	Lung arginase expression and activity is increased in cystic fibrosis mouse models. Journal of Applied Physiology, 2014, 117, 284-288.	2.5	11
89	Neuropsychological outcomes following pediatric lung transplantation. Pediatric Pulmonology, 2020, 55, 2427-2436.	2.0	8
90	Quality of life outcomes following pediatric lung transplantation. Pediatric Pulmonology, 2017, 52, 1495-1501.	2.0	7

#	Article	IF	Citations
91	Long-term effect of CFTR modulator therapy on airway nitric oxide. European Respiratory Journal, 2020, 55, 1901113.	6.7	7
92	An Integrated Clinical and Genetic Prediction Model for Tacrolimus Levels in Pediatric Solid Organ Transplant Recipients. Transplantation, 2021, Publish Ahead of Print, .	1.0	7
93	Arginine Metabolism in Patients with Cystic Fibrosis. Journal of Pediatrics, 2013, 163, 317-319.	1.8	6
94	New Developments in Cystic Fibrosis Airway Inflammation. Mediators of Inflammation, 2015, 2015, 1-2.	3.0	6
95	Evaluation of clinically relevant changes in the lung clearance index in children with cystic fibrosis and healthy controls. Thorax, 2023, 78, 362-367.	5.6	6
96	Ventilatory responses to acute hypoxia in neurokinin-1 receptor deficient mice. Respiratory Physiology and Neurobiology, 2007, 159, 227-231.	1.6	5
97	Multitracer Stable Isotope Quantification of Arginase and Nitric Oxide Synthase Activity in a Mouse Model of Pseudomonas Lung Infection. Mediators of Inflammation, 2014, 2014, 1-7.	3.0	5
98	Plasma arginine metabolites reflect airway dysfunction in a murine model of allergic airway inflammation. Journal of Applied Physiology, 2015, 118, 1229-1233.	2.5	5
99	Pediatric Emergency Department Use of Intranasal Fentanyl to Treat Pain in Children with Sickel Cell Disease and Its Impact on Discharge Rates: A Multicenter Perspective. Blood, 2016, 128, 1306-1306.	1.4	5
100	Nasal nitric oxide is reduced in children after solid-organ transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 108-109.	0.6	4
101	Metabolic origins of childhood asthma. Molecular and Cellular Pediatrics, 2015, 2, 6.	1.8	4
102	Inflammatory epithelial cytokines after in vitro respiratory syncytial viral infection are associated with reduced lung function. ERJ Open Research, 2021, 7, 00365-2021.	2.6	4
103	Comparative analysis of respiratory symptom scores to detect acute respiratory events in children with cystic fibrosis. Journal of Cystic Fibrosis, 2023, 22, 296-305.	0.7	3
104	Increased Arginase Expression and Decreased Nitric Oxide in Pig Donor Lungs after Normothermic Ex Vivo Lung Perfusion. Biomolecules, 2020, 10, 300.	4.0	2
105	Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis. European Respiratory Journal, 2020, 56, 2000175.	6.7	2
106	Aquagenic wrinkling of the palms in cystic fibrosis patients treated with ivacaftor. Journal of Cystic Fibrosis, 2022, 21, e102-e105.	0.7	2
107	How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease be Monitored?. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	2
108	Do the cysteine proteinases cathepsin B and S contribute to cystic fibrosis lung disease?. Pediatric Pulmonology, 2010, 45, 845-846.	2.0	1

#	Article	IF	Citations
109	Asymmetric Dimethylarginine (ADMA) In Cystic Fibrosis Lung Disease. , 2010, , .		1
110	Editorial [Hot Topic: New Developments in Pharmaceutical Treatments for Cystic Fibrosis (Executive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.9	1
111	Asymmetric-Dimethylarginine. , 2017, , 247-254.		1
112	Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations. Pediatric Pulmonology, 2021, 56, 2036-2042.	2.0	1
113	Association of wheeze with lung function decline in children with sickle cell disease. European Respiratory Journal, 2017, 50, 1602433.	6.7	1
114	Lower Airway Nitrogen Oxide Levels in Children with Primary Ciliary Dyskinesia Is Linked to Neutrophilic Inflammation. Journal of Pediatrics, 2022, 244, 230-233.	1.8	1
115	Interleukin-1 beta is a potential mediator of airway nitric oxide deficiency in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 623-625.	0.7	1
116	An association of the arginase 1 gene with preschool wheezing phenotypes. Pediatric Pulmonology, 2021, 56, 1821-1822.	2.0	0
117	Nitric Oxide and Nitrogen Oxides. , 2022, , 426-442.		0
118	The Trp64Arg polymorphism in the Î² ₃ â€adrenergic receptor gene is not associated with pulmonary function in cystic fibrosis. FASEB Journal, 2006, 20, .	0.5	0
119	Pediatric Emergency Department Adherence to the 2014 National Heart, Lung and Blood Institute Guidelines Targeting Analgesic Therapy in the Management of Vaso-Occlusive Pain Episodes in Children with Sickle Cell Disease: a Multicenter Perspective. Blood, 2016, 128, 1016-1016.	1.4	0